Enhanced oral bioavailability of 10-hydroxycamptothecin through the use of poly (n-butyl cyanoacrylate) nanospheres
- PMID: 28481657
- DOI: 10.1080/03639045.2017.1328432
Enhanced oral bioavailability of 10-hydroxycamptothecin through the use of poly (n-butyl cyanoacrylate) nanospheres
Abstract
The article describes the preparation, physicochemical characterization, drug release, and in vivo behavior of 10-hydroxycamptothecin-loaded poly (n-butyl cyanoacrylate) (PBCA) nanospheres (HCPT-PBCA-NSs). HCPT-PBCA-NSs were successfully prepared via emulsion polymerization of n-butyl cyanoacrylate (BCA) monomer in acidic medium with the aid of two colloidal stabilizers (Poloxamer 188 and Dextran 70). The influence of pH, the time of polymerization, and the dosage of the drug on particle size and encapsulation efficiency (EE) were studied. HCPT-PBCA-NSs were of spherical shape and uniformly dispersed with a particle size of 135.7 nm, and zeta potential of -18.18 mV. EE, drug loading (DL), and yield of HCPT-PBCA-NSs were 51.52, 0.63, and 88.25%, respectively. FTIR, 1H NMR, and DSC showed complete polymerization of BCA monomer and HCPT existed in the form of molecular or amorphous in NSs. In vitro release of the drug from HCPT-PBCA-NSs exhibited sustained-release behavior with an initial burst release and about 60% of HCPT was released from the formulation within 24 h of dialysis. The pharmacokinetic study in healthy rats after oral administration showed that encapsulation of HCPT into PBCA-NSs increased the Cmax about 3.84 times and increased AUC0-t about 5.40 times compared with that of HCPT suspension. It was concluded that PBCA-NSs could be a promising drug carrier to load HCPT for oral drug delivery if efforts are made in the future to improve its poor DL capacity.
Keywords: 10-Hydroxycamptothecin; emulsion polymerization; oral drug delivery; pharmacokinetics; poly (n-butyl cyanoacrylate) nanospheres.
Similar articles
-
In vitro and in vivo evaluation of 10-hydroxycamptothecin-loaded poly (n-butyl cyanoacrylate) nanoparticles prepared by miniemulsion polymerization.Colloids Surf B Biointerfaces. 2018 Feb 1;162:25-34. doi: 10.1016/j.colsurfb.2017.11.029. Epub 2017 Nov 12. Colloids Surf B Biointerfaces. 2018. PMID: 29145001
-
Box-Behnken optimization design and enhanced oral bioavailability of thymopentin-loaded poly (butyl cyanoacrylate) nanoparticles.Pharmazie. 2011 May;66(5):339-47. Pharmazie. 2011. PMID: 21699067
-
Effects of phospholipid and polyethylene glycol monostearate (100) on the in vitro and in vivo physico-chemical characterization of poly(n-butyl cyanoacrylate) nanoparticles.Colloids Surf B Biointerfaces. 2019 Jan 1;173:320-326. doi: 10.1016/j.colsurfb.2018.10.002. Epub 2018 Oct 3. Colloids Surf B Biointerfaces. 2019. PMID: 30312943
-
Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 Jan-Feb;2(1):35-47. doi: 10.1002/wnan.59. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010. PMID: 20049829 Review.
-
Emulsion Techniques for the Production of Pharmacological Nanoparticles.Macromol Biosci. 2019 Jun;19(6):e1900063. doi: 10.1002/mabi.201900063. Epub 2019 Apr 24. Macromol Biosci. 2019. PMID: 31016873 Review.
Cited by
-
Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities.Pharmaceuticals (Basel). 2020 Mar 11;13(3):44. doi: 10.3390/ph13030044. Pharmaceuticals (Basel). 2020. PMID: 32168743 Free PMC article.
-
Poly (n-butyl cyanoacrylate) as a nanocarrier for rivastigmine transport across the blood-brain barrier in Alzheimer's disease treatment: a perspective from molecular dynamics simulations.J Mol Model. 2018 Aug 25;24(9):252. doi: 10.1007/s00894-018-3799-0. J Mol Model. 2018. PMID: 30145721
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources